MINNEAPOLIS (October 9, 2017) – This week, OneOme will participate in the Individualizing Medicine 2017 Conference in Rochester, Minn. The event, which is hosted by the Mayo Clinic Center for Individualized Medicine, features experts from around the world sharing advice on the practical application of genomic and precision medicine.

OneOme will have an exhibit throughout the two-day conference and its team will share their pharmacogenomic expertise through a poster and theater presentation. OneOme’s RightMed® solution has the potential to address the crisis of adverse drug reactions and drug ineffectiveness by analyzing how a person’s genes may predict their response to medications. Pharmacogenomics can improve patient health by increasing drug effectiveness, as well as decreasing side effects, adverse drug reactions, and unintended interactions with other medications.

On Monday, October 9 from noon to 12:15 p.m., Don Skifter, PhD, VP Business Development and Clinical Support, will speak on “Considerations for Broadly Adopting Pharmacogenomics within a Health System.”

Later on Monday, from 5 p.m. to 7:30 p.m., clinical development pharmacist Kathleen Bosse, PharmD, will present at the poster reception at the Mayo Civic Center. The poster describes a case study on CYP2C9*2 that explores the substrate-specificity of allele functions and considerations for pharmacogenomics implementation. Co-authors on the poster include Isabelle Iltis-Searcy, PhD, Hennessy McIlvaine, BA, Ross Higgins, MBA, MLS (ASCP), and Bronwyn Ramey-Hartung, PhD.

WHAT: OneOme participates in Individualizing Medicine 2017 Conference

WHERE: Mayo Civic Center 30 Civic Center Drive Southeast Rochester, Minn.

WHEN: Monday, October 9, 2017
Noon – Theater presentation by Don Skifter, PhD
5-7:30 p.m. – Poster presentation by Kathleen Bosse, PharmD

OneOme will also host an exhibit throughout the conference (Oct. 9-10).

OneOme’s RightMed solution better enables providers to more effectively treat conditions in primary care and a variety of specialty areas, including mental health, cancer, heart disease, pain and more. The RightMed comprehensive test covers hundreds of medications at an accessible price point. To date, over 450 locations from over 22 different countries have ordered OneOme’s RightMed test and OneOme continues to build research and commercial partnerships across the globe.

About OneOme
The OneOme platform was co-developed and exclusively licensed from Mayo Clinic to bring pharmacogenomics into routine clinical care. OneOme is a privately held company backed by early-stage venture firm Invenshure, LLC, and Mayo Clinic. To learn more, visit oneome.com.

Editor’s Note: Mayo Clinic has financial investment in the technology referenced in this news release. The revenue that Mayo Clinic will receive is used to support its not-for-profit mission in patient care, education and research.